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ABSTRACT: The TRPV4 calcium-permeable cation channel plays
important physiological roles in osmosensation, mechanosensation, cell
barrier formation, and bone homeostasis. Recent studies reported that
mutations in TRPV4, including some in its ankyrin repeat domain (ARD),
are associated with human inherited diseases, including neuropathies and
skeletal dysplasias, probably because of the increased constitutive activity
of the channel. TRPV4 activity is regulated by the binding of calmodulin
and small molecules such as ATP to the ARD at its cytoplasmic N-
terminus. We determined structures of ATP-free and -bound forms of
human TRPV4-ARD and compared them with available TRPV-ARD
structures. The third inter-repeat loop region (Finger 3 loop) is ﬂexible
and may act as a switch to regulate channel activity. Comparisons of TRPV-ARD structures also suggest an evolutionary link
between ARD structure and ATP binding ability. Thermal stability analyses and molecular dynamics simulations suggest that
ATP increases stability in TRPV-ARDs that can bind ATP. Biochemical analyses of a large panel of TRPV4-ARD mutations
associated with human inherited diseases showed that some impaired thermal stability while others weakened ATP binding
ability, suggesting molecular mechanisms for the diseases.
T
ransient receptor potential (TRP) channels are cation
channels involved in sensation of various stimuli from
internal and external environments. The TRP channel super-
family is divided into six subfamilies in mammals: canonical or
classical TRPC, vanilloid TRPV, melastatin TRPM, ankyrin
TRPA, mucolipin TRPML, and polycystin TRPP.
1−3 Six TRPV
proteins, TRPV1−6, belong to the vanilloid subfamily. TRPV
proteins function as tetramers, and each protomer contains six
transmembrane segments ﬂanked by two intracellular domains:
a large N-terminal domain containing ankyrin repeats and a
short C-terminal domain.
TRPV channel activity is regulated by post-translational
modiﬁcations such as phosphorylation or binding of regulatory
molecules to intracellular domains.
4,5 In TRPV1, for example,
ATP and calmodulin (CaM) have been shown to bind to the
N-terminal ankyrin repeat domain (ARD) and sensitize and
desensitize channel activity, respectively.
6,7 The binding of ATP
and CaM to the ARD is also conserved in TRPV4 and TRPV3.
8
Phosphatidylinositol 4,5-bisphosphate (PIP2) and CaM interact
with the C-terminal domain of TRPV1 and regulate channel
activity.
9−11 The molecular mechanisms by which these
intracellular signals regulate TRPV channel activity remain
unclear.
TRPV4 is a member of the TRPV subfamily expressed
broadly in neuronal and non-neuronal cells. TRPV4 is activated
by various stimuli, including hypo-osmolarity, warm temper-
ature, and chemical ligands such as 4-α-phorbol esters and
epoxyeicosatrienoic acids.
12−15 Consistent with these in vitro
ﬁndings, TRPV4 has been implicated in physiological functions
such as osmoregulation and thermoregulation.
16,17 TRPV4 also
plays a role in mechanosensation in the vascular endothelium
and unitary tract,
18 and cell barrier formation in vascular and
epidermal tissues.
19 Recently, studies using TRPV4 knockout
mice suggested the functional importance of TRPV4 in the
central nervous system, nociception, and bone formation.
20−22
Mutations in TRPV4 are associated with a wide spectrum of
inherited diseases, primarily autosomal dominant neuropathies
and skeletal dysplasias.
23,24 Several mutants studied in
heterologous expression systems showed constitutive basal
activity and enhanced response to stimuli.
25−28 These ﬁndings
are consistent with cell death caused by high calcium inﬂux
such as the observed degeneration of motor neurons in
neuropathies.
27,28 However, it is diﬃcult to explain how
seemingly similar molecular properties lead to such diverse
disease phenotypes. It is therefore essential to elucidate how
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mechanisms behind these inherited diseases.
To obtain insight into regulatory mechanisms of TRPV4, we
focused on TRPV4-ARD, which can mediate channel regulation
through binding of ligands to its concave surface and is the
target of many mutations causing human diseases. We
determined the structures of ATP-free and -bound human
TRPV4-ARD and compared them with the structures of the
other TRPV-ARDs. Despite a number of TRPV-ARD
structures available in the absence or presence of ATP, this
represents the ﬁrst cognate pair of ATP-free and -bound
structures. Structural analysis revealed that a long loop forming
Finger 3 is ﬂexible and could switch conformation to possibly
regulate channel activity. Comparisons of TRPV-ARD
structures provide further insights into the evolution of ATP
binding in TRPV channels. Thermal stability analyses, a
cysteine accessibility assay, and molecular dynamics (MD)
simulations indicate that ATP binding can stabilize TRPV1-
and TRPV4-ARD. Interestingly, most mutations causing
human genetic diseases in TRPV4-ARD are located away
from the ATP-binding site, suggesting that additional regulatory
interactions and mechanisms exist. A series of biochemical
analyses of disease-associated mutants showed that some
impaired thermal stability and/or ATP binding ability,
providing biochemical insights into possible disease mecha-
nisms.
■ EXPERIMENTAL PROCEDURES
Expression Constructs. Human TRPV4 cDNA was
obtained from C. J. Sumner. The DNA fragment corresponding
to the ARD (residues 149−396) was ampliﬁed by polymerase
chain reaction and subcloned into the NdeI and NotI sites of a
pET vector with a C-terminal six-histidine tag (pET21-C6H).
29
Mutations were generated with QuikChange (Stratagene) and
conﬁrmed by DNA sequencing.
P r o t e i nP r o d u c t i o na n dP u r i ﬁcation. Recombinant
human TRPV4-ARD protein was expressed in Escherichia coli
BL21(DE3) by induction with 75 μM isopropyl β-D-
thiogalactopyranoside for 13 h at room temperature after the
cells reached an OD600 of ∼0.6. Frozen cell pellets were thawed,
resuspended, and lysed by sonication in lysis buﬀer [20 mM
Tris-HCl, 300 mM NaCl, and 20 mM imidazole (pH 7.0)] with
1 mM benzamidine, 1 mM phenylmethanesulfonyl ﬂuoride
(PMSF), 0.1% Triton X-100, 0.2 mg/mL lysozyme, 50 μg/mL
RNase A, and 25 μg/mL DNase I. The lysate was cleared by
centrifugation and the supernatant loaded onto nickel-nitrilotri-
acetic acid (Ni-NTA) agarose (Qiagen) and eluted with a step
gradient containing 25, 50, 100, 150, 200, and 250 mM
imidazole (pH 7.0) in lysis buﬀer with 0.05% β-mercaptoetha-
nol and 0.5 mM PMSF. Fractions containing the protein at 150,
200, and 250 mM imidazole were combined, and EDTA (pH
8.0) was added to a ﬁnal concentration of 1 mM and then the
mixture dialyzed against 20 mM Tris-HCl (pH 7.0), 50 mM
NaCl, 1 mM EDTA, and 1 mM DTT. The dialyzed protein was
puriﬁed on SP Sepharose FF (GE Healthcare, Piscataway, NJ)
in 20 mM Tris-HCl (pH 7.0), 1 mM EDTA, and 1 mM DTT
using a linear gradient from 0 to 0.4 M NaCl. Size exclusion
chromatography on a Superdex 75 column (GE Healthcare) in
10 mM Tris-HCl (pH 7.0), 300 mM NaCl, 10% glycerol, and 1
mM DTT was used for ﬁnal puriﬁcation. Protein was
concentrated to ∼8 mg/mL in a Vivaspin centrifugal ﬁlter
(10000 molecular weight cutoﬀ; Sartorius AG, Goettingen,
Germany), ﬂash-frozen, and stored at −80 °C. In the
puriﬁcation of mutant proteins for the thermal stability assay,
dialysis and ion exchange steps were omitted. After Ni-NTA
puriﬁcation, the proteins were puriﬁed by size exclusion
chromatography in phosphate-buﬀered saline (pH 7.4) with 1
mM DTT. Rat TRPV1-ARD (rTRPV1-ARD) was puriﬁed as
described previously.
7
Crystallization of Human TRPV4-ARD. Crystals were
grown by hanging-drop vapor diﬀusion at 4 °C: the ATP-free
form with a 1:3 ratio of protein to reservoir solution [0.35 M
NaH2PO4, 0.35 M KH2PO4, 10% glycerol, and 0.1 M Na-
HEPES (pH 7.8)] and the ATP-bound form with a 1:1 ratio of
protein to reservoir [3% PEG 4000, 10% glycerol, and 0.1 M
Na-HEPES (pH 7.9)] in the presence of 5 mM ATP. Crystals
were soaked in reservoir solution containing 15% glucose for 3
min, transferred into reservoir solution containing 30% glucose,
and ﬂash-frozen in liquid nitrogen.
Data Collection, Structure Determination, and Anal-
ysis. X-ray data were collected at 100 K using an ADSC Q315
detector at the Advanced Photon Source ID24 beamline,
processed in HKL2000;
30 data statistics are listed in Table 1.
The hTRPV4-ARD structures were determined by molecular
replacement using the chicken TRPV4-ARD structure in
MOLREP
31 and Phaser.
32 Model building was performed in
COOT
33 and reﬁnement with TLS (Translation/Libration/
Screw) in REFMAC5.
34 Final reﬁnement statistics are listed in
Table 1. The coordinates have been deposited in the Protein
Data Bank (PDB) as entries 4DX1 (ATP-free) and 4DX2
(ATP-bound). Figures were generated with PyMOL (Schrö-
dinger, LLC).
Thermal Stability Assay by Circular Dichroism Spec-
troscopy. Circular dichroism (CD) spectra were measured at
10 °C with 3.4 μM protein in 150 mM NaCl, 5 mM Tris-HCl
(pH 7.5), and 1 mM DTT for experiments testing the inﬂuence
of ATP on protein stability, and in phosphate-buﬀered saline
(pH 7.4) with 1 mM DTT for analyses of the wild type and
mutants. CD spectra were recorded in a 1 mm path length
cuvette on a Jasco J-815 spectropolarimeter. For thermal
stability, the molar ellipticity at λ = 222 nm was measured as
the protein solutions were heated at a rate of 1 °C/min and
used to determine the fraction of protein folded (assuming a
completely folded protein population at a starting temperature
of 10 °C). Thermal denaturation temperatures (Tm) were
analyzed with Jasco Spectra software (JASCO Inc., Easton,
MD) and are given with their standard deviation (SD).
Molecular Dynamics Simulation of rTRPV1-ARD. Two
sets of molecular dynamics simulations (apo and ATP) were
conducted using the structure of rTRPV1-ARD bound to ATP,
with and without the ATP ligand removed in silico, respectively
(PDB entry 2PNN, residues 111−356). Structures were
solvated in explicit water (TIP3) and ions (100 mM NaCl)
using VMD.
35 The systems contained 208501 (ATP) and
208482 (apo) atoms. Minimization, equilibration, and steered
molecular dynamics (SMD) simulations were performed in
multiple steps using NAMD2.7,
36 the CHARMM27 force ﬁeld
for proteins with the CMAP correction,
37,38 full electrostatics,
and 2 fs time steps with hydrogen bonds constrained. SMD
simulations stretched both ends of TRPV1-ARD at eﬀective
speeds of 2 and 20 nm/ns.
ATP-Agarose Pull-Down Assays. The ATP-agarose assays
were performed as described previously.
28 Brieﬂy, 20 μgo f
protein was incubated with 70 or 75 μL of a 50% ATP agarose
slurry for 1 h at 4 °C in binding buﬀer [10 mM Tris-HCl (pH
7.0), 50 mM NaCl, 1 mM DTT, and 0.15% n-decyl D-
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times, proteins were extracted and loaded onto the 15% SDS
gel. In each load lane, the volumes loaded corresponded to 1 μg
of protein. Gels were quantiﬁed using ImageJ (National
Institutes of Health, Bethesda, MD), and shown are the
averages ± SD for three independent experiments.
TRPV1 Cysteine Modiﬁcation Assay. Reaction mixtures
containing rTRPV1-ARD (8.5 μM) in 150 mM NaCl, 20 mM
Tris (pH 7.0), 0.5 mM PEG-maleimide 5 kDa (Creative
PEGWorks), and 10 mM nucleotide as indicated were
incubated at room temperature, reactions stopped by addition
of DTT to a ﬁnal concentration of 110 mM, and mixtures
analyzed by Coomassie-stained 12% SDS−PAGE.
Statistical Analyses. Statistical signiﬁcance was tested by
multiple comparisons using Tukey-Kramer or Dunnett’s
method with JMP software (SAS Institute Inc., Cary, NC).
■ RESULTS
Structures of Human TRPV4-ARD. Recombinant human
TRPV4-ARD (hTRPV4-ARD, residues 149−396) produced in
E. coli was puriﬁed for structure determination by X-ray
crystallography and biochemical analyses. We determined the
structure of hTRPV4-ARD in the absence (crystal form I, ATP-
free) or presence (crystal form II) of ATP (Table 1). Both
crystal forms contain two molecules per asymmetric unit. In
crystal form II, one molecule is bound to ATP (ATP-bound)
while the other is not (ATP-unbound). As expected on the
basis of previous structures of TRPV-ARDs,
7 hTRPV4-ARD
consists of six ankyrin repeats (ANK1−6) each containing an
inner and an outer helix followed by a connecting ﬁnger loop
(Fingers 1−5) (Figure 1A). The inner helices and ﬁngers form
a concave surface to which ATP is bound at the expected site
previously identiﬁed in TRPV1.
7 Importantly, these structures
represent the ﬁrst cognate pair of ATP-bound and ATP-free
TRPV-ARD structures.
The structures of hTRPV4-ARD were compared to each
other and to those of chicken TRPV4-ARD (cTRPV4-ARD).
28
The structures of ATP-free hTRPV4-ARD and cTRPV4-ARD
(residues 133−382, 90% identical sequences) are very similar
(rmsd ranges from 0.635 to 0.922 Å over 239−242 Cα atoms)
Table 1. Data Collection and Reﬁnement Statistics
crystal form I (ATP-free) crystal form II (with ATP)
Data Collection
space group P3121 P3221
wavelength (Å) 0.97917 0.97917
cell dimensions
a, b, c (Å)
53.30, 53.37, 440.71 147.89, 147.89, 93.90
resolution (Å)
a 40.0−2.85 (2.90−2.85) 40.0−2.95 (3.00−2.95)
Rsym
a 0.115 (0.614) 0.099 (0.714)
I/σ(I)
a 12.3 (1.8) 17.6 (2.4)
completeness
(%)
a 99.6 (99.3) 100.0 (100.0)
redundancy
a 5.3. (5.4) 5.5 (5.6)
Reﬁnement
resolution (Å)
a 39.2−2.85 (2.92−2.85) 38.86−2.95 (3.03−2.95)
no. of reﬂections 17306 23958
Rwork/Rfree 0.215/0.278 0.177/0.220
no. of molecules
per asymmetric
unit
22
no. of residues in
model
148−397 (chain A) 148−394 (ATP-bound)
148−396 (chain B) 148−392 (ATP-unbound)
no. of atoms
protein 1995 (chain A) 1987 (ATP-bound)
1986 (chain B) 1963 (ATP-unbound)
ligand 25 (PO4) 31 (ATP)
6 (glycerol) 6 (glycerol)
12 (glucose)
water 18 72
B factor (Å)
protein 80.91 62.12 (ATP-bound)
72.76 (ATP-unbound)
ligand 113.98 (PO4) 91.00 (ATP)
103.44 (glycerol) 72.51 (glycerol)
90.86 (glucose)
water 76.06 54.84
rmsd
bond
lengths
(Å)
0.013 0.013
bond
angles
(deg)
1.51 1.80
aValues from the highest-resolution shell are in parentheses.
Figure 1. Structural comparison of human and chicken TRPV4-ARDs.
(A) Superimposed ribbon diagrams of ATP-bound (magenta) and
ATP-free (blue) hTRPV4-ARD. ATP is shown as sticks. (B)
Superimposed Cα traces of human and chicken TRPV4-ARD. Finger
3 is twisted and shrunken in the ATP-bound (magenta) and ATP-
unbound (green) hTRPV4-ARD structures, while the ﬁnger is
extended in ATP-free hTRPV4-ARD (blue) and cTRPV4-ARD
(gray). Several Finger 3 residues are disordered in three of six
TRPV4-ARD structures. The structure of Finger 2 in the ATP-bound
and -unbound forms diﬀers from that in ATP-free forms.
Biochemistry Article
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trend is apparent when extending this comparison to all 10
available structures of TRPV4-ARD (four hTRPV4-ARD
molecules in two crystal forms and six cTRPV4-ARD molecules
in two crystal forms as well), with large structural diﬀerences
observed in the very long Finger 3, as well as in the tip of
Finger 2. Consistently, Finger 3 residues had high B factors and
were too disordered to trace in several cTRPV4-ARD
structures, indicating high ﬂexibility.
Structural Consequences of ATP Binding. Direct
comparisons of the ATP-free and ATP-bound hTRPV4-ARD
structures again show conformational diﬀerences restricted to
Fingers 2 and 3 (Figure 1A). Finger 3 was extended in ATP-
free hTRPV4-ARD (and in ATP-free cTRPV4-ARD), while the
ﬁnger loop was twisted and shrunken in ATP-bound hTRPV4-
ARD. Finger 2 was also slightly twisted in ATP-bound
hTRPV4-ARD. Surprisingly, both conformational diﬀerences
were also observed when comparing the second, ATP-
unbound, molecule in crystal form II to the ATP-free crystal
form I structures (Figure 1B). In crystal form II, an adjacent
symmetry-related hTRPV4-ARD molecule occupied the ATP-
binding site of the ATP-unbound molecule, possibly mimicking
ATP binding. Alternatively, the shrunken Finger 3 structure
may result from crystal contacts and/or crystallization
condition diﬀerences.
One unusual feature of TRPV-ARDs is that many aromatic
residues are exposed on ﬂexible Fingers 2 and 3.
29 In hTRPV4-
ARD, 9 of 20 aromatic residues are located on the concave face
of Fingers 2 and 3 [three and six residues, respectively (Figure
2)]. Interestingly, F272 and F273 on Finger 3 are exposed in
the ATP-free form, while these phenylalanines are buried in the
shrunken Finger 3 of the ATP-bound form (Figure 2B). The
observed conformational diﬀerences may thus serve to regulate
the exposure of the aromatic patch, and the conservation of the
patch suggests that it is important, perhaps in interactions with
regulatory ligands or with other regions of the full TRPV4
homotetramer.
Structural Comparison of TRPV-ARDs. Multiple TRPV-
ARD structures are available: a structure of rat TRPV1-ARD
(rTRPV1-ARD) bound to ATP,
7 structures of cTRPV4-ARD in
the absence of ATP, and structures of several ARDs that do not
bind ATP, namely, rat and human TRPV2-ARDs and mouse
TRPV6-ARD
28,39,40 (see Table S1 of the Supporting
Information). The overall structures of all available TRPV-
ARDs are similar, with rmsd values ranging from 0.637 to 1.865
Å over 139−155 core Cα atoms (Table S2 of the Supporting
Information). A superposition of all structures illustrates that
the largest structural diﬀerences are again found in Fingers 2
and 3 (Figure 3A). Structural comparisons of these TRPV-
ARDs and the new human TRPV4-ARD highlight three
noteworthy features.
First, as expected from biochemical, mutational, and
sequence analyses,
8 the interaction of ATP with hTRPV4-
ARD is very similar to what was previously observed in
rTRPV1-ARD (Figure 3B).
7 The adenine base ﬁts in a
conserved pocket, stacking against Tyr236 and hydrogen
bonding to Gln239. Furthermore, Lys192 and Lys197 on the
surface of inner helix 2 interact with the phosphate groups of
ATP. These lysines are homologous to lysines critical for ATP
binding in rTRPV1-ARD (Lys155 and Lys160)
7 and cTRPV4-
ARD (Lys178 and Lys183).
8 The importance of Lys197 in ATP
binding is further discussed below. The γ-phosphate of the ATP
is further removed from the protein in TRPV4 compared to
TRPV1, consistent with the fact that TRPV4-ARD exhibited
less selectivity for ATP over ADP in ATP-agarose competition
assays.
7
Second, the backbone structure of ATP-bound hTRPV4-
ARD, with a collapsed Finger 3, is quite similar to those of
TRPV2-ARD and TRPV6-ARD, which lack the ability to bind
ATP (Figure 3C). In contrast, the ATP-free structures of
chicken and human TRPV4-ARD, which both have the ability
to bind ATP, have extended Finger 3 conformations (Figures
1B and 3A). This visual observation is supported by a
comparison of rmsd values for Fingers 2 and 3 of both ATP-
free and -bound forms of hTRPV4-ARD with TRPV2-ARDs
and mTRPV6-ARD: the ATP-bound form generally showed
smaller rmsds than the ATP-free form (Table S2 of the
Supporting Information). This suggests that although the ARDs
of TRPV2 and TRPV6 do not bind ATP, they are closest to the
ATP-bound state of ARDs with ATP-binding sites, at least in
structural terms.
Finally, the structure of ATP-bound hTRPV4-ARD and
comparisons to TRPV2 and TRPV6 suggest that a previously
unrecognized residue, Phe231 in hTRPV4-ARD, could be
important for ATP binding. Phe231 is located under the
adenine-stacking Tyr236 on Finger 2 (Figure 3D), contributing
to the adenine-binding pocket. This aromatic residue is
conserved in the ATP-binding site of rTRPV1-ARD
(Tyr194), while the aromatic residues are substituted with a
smaller aliphatic residue, cysteine or methionine, in TRPV2 or
TRPV6, respectively (Figure 3E). Sequence alignments of
TRPV proteins conﬁrm this trend, as the equivalent residue is a
Figure 2. Aromatic residues on Fingers 2 and 3 have varied positions
in hTRPV4-ARD structures. (A) The hTRPV4-ARD structures of
ATP-bound (magenta), ATP-unbound (green), and ATP-free (blue)
forms are superimposed. Aromatic residues are shown as sticks. (B)
Detail of the Finger 2 and 3 loops. F272 and F273 on Finger 3 (black
rectangles) are embedded in the aromatic cluster in the ATP-bound
and -unbound forms but exposed in the ATP-free form. Y235 and
Y236 on Finger 2 and Y281 and F282 on Finger 3 are located in
similar positions but show variable orientations. F231, F282, Y283, and
F284 show less variation.
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TRPV5, which does not. Substitution of these aromatic residues
with cysteine (the residue found in the equivalent position in
TRPV2) caused a signiﬁcant reduction in the level of ATP
binding in both rTRPV1-ARD and hTRPV4-ARD. In rTRPV1-
ARD, the Y194C mutation reduced the level of ATP binding
comparably to the K155A mutation identiﬁed in a previous
study (Figure 3F).
7 A signiﬁcant reduction in the level of ATP
binding was also observed in hTRPV4-ARD mutant F231C
(Figure 3G). These results indicate that the buried aromatic
residue in Finger 2 conserved in TRPV1, TRPV3, and TRPV4
does indeed contribute to ATP binding in rTRPV1-ARD and
hTRPV4-ARD.
ATP Binding Stabilizes TRPV4-ARD and TRPV1-ARD.
ATP binding does not result in large conformational changes,
but the ATP-bound form showed a tightly packed Finger 3 in
both rTRPV1-ARD and hTRPV4-ARD structures, leading us to
hypothesize that ATP may stabilize the proteins. In other
ankyrin repeat proteins, such as IκBα and Notch, the ankyrin
repeats are partially folded and complete their folding as a
ligand is bound.
41−43 We therefore sought to determine
whether ATP binding aﬀected ARD stability. To this end, we
analyzed the thermal stability of hTRPV4-ARD by CD
spectroscopy in the absence or presence of ATP, AMP, or
phosphate (Figure 4). In buﬀer alone, hTRPV4-ARD showed a
melting temperature (Tm) of 37.1 ± 0.1 °C. Phosphate ions (1
mM) increased Tm slightly but not signiﬁcantly (37.33 ± 0.07
°C). In the presence of nucleotide ligands (1 mM), however, a
small but signiﬁcant increase in Tm was observed (Tm = 37.9 ±
0.2 °C for ATP and 37.4 ± 0.2 for AMP). The greater
stabilization observed with ATP compared to AMP matches
their diﬀering binding aﬃnity observed with cTRPV4-ARD.
8
Stabilization of the ARD fold by nucleotides may also aﬀect
the accessibility of buried cysteine residues. hTRPV4-ARD
contains four cysteines, two exposed (Cys194 and Cys250) and
two buried (Cys294 and Cys353; Figure S1 of the Supporting
Information). We examined the eﬀect of ATP binding on ARD
stability by measuring the kinetics of cysteine modiﬁcation with
PEG-maleimide (mPEG) in the presence or absence of 10 mM
AMP or ATP. hTRPV4-ARD was modiﬁed at endogenous
cysteines by a 5 kDa PEG-maleimide, resulting in multiple
shifted bands on SDS−PAGE. Furthermore, the rate of protein
modiﬁcation with mPEG was signiﬁcantly reduced in the
presence of nucleotides, especially ATP (Figure S1 of the
Supporting Information). This suggests that the ARD fold is
quite ﬂexible, and that ATP binding stabilizes the fold,
consistent with the thermal stability results described above.
Figure 3. Structural comparison of TRPV-ARDs. (A) Superimposed
main chain structure of TRPV-ARDs (rTRPV1-ARD, gray; rat and
human TRPV2-ARD, cyan; ATP-bound hTRPV4-ARD, magenta;
ATP-unbound hTRPV4-ARD, green; ATP-free hTRPV4-ARD, blue;
and mouse TRPV6-ARD, black). Finger 3 and a part of Finger 2 are
highly ﬂexible. Several residues on Finger 3 are missing in one of two
TRPV1-ARD structures and four of seven TRPV2-ARD structures.
(B) ATP-binding site of hTRPV4-ARD and rTRPV1-ARD. Residues
(sticks) within 4 Å of the ATP molecule and a surface map of the
ATP-binding site in hTRPV4-ARD (left) and the corresponding
residues in the rTRPV1-ARD ATP-binding site (right). The bBound
ATP molecule is shown as sticks (orange and yellow). (C) Finger 2
(2) and Finger 3 (3) structures of ATP-bound rat TRPV1-ARD
(gray), rat and human TRPV2-ARD (cyan), human ATP-bound
Figure 3. continued
TRPV4-ARD (magenta), and mouse TRPV6-ARD (black). (D)
Aromatic residue positioned behind the adenine base of ATP in
Finger 2 (F231 in human TRPV4-ARD). (E) This aromatic residue is
conserved in TRPV-ARDs that bind ATP (red rectangle). (F and G)
ATP-agarose pull-down assays for wild-type and mutant rTRPV1-ARD
(F) or hTRPV4-ARD (G). Coomassie-stained gels (top) of wild-type
and mutant proteins loaded (left) and bound to ATP-agarose in the
absence (middle) or presence (right) of competing free ATP. The
normalized intensity of protein recovered (mean ± SD; n =3 )i s
plotted below. The statistical signiﬁcance of the change in binding to
ATP-agarose with respect to the wild type (WT) was determined by a
multiple-comparison test using Dunnett’s method, with p < 0.01
indicated by an asterisk.
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ARD stability, we used single-cysteine mutants, allowing us to
speciﬁcally address the accessibility of a buried cysteine.
Interestingly, rTRPV1-ARD possesses a cysteine residue
accessible to chemical modiﬁcation by allicin, the active
compound in garlic extract.
44 This cysteine residue, Cys157
(corresponding to Cys194 in hTRPV4-ARD), is paradoxically
buried within the hydrophobic core of TRPV1-ARD (Figure
5A), suggesting that the structure may have some ﬂexibility in
solution, similar to that hypothesized for TRPV4-ARD above.
Indeed, rTRPV1-ARD was modiﬁed at endogenous cysteines,
like hTRPV4-ARD, whereas no mobility shift was observed in a
cysteine-less rTRPV1-ARD variant (CL) (Figure 5B). More
importantly, PEG-maleimide modiﬁcation of a single-cysteine
variant (C157) of rTRPV1-ARD, in which all cysteines except
Cys157 were substituted with serine (C126S/C257S/C362S),
resulted in a single shifted band (Figure 5B). This result
demonstrates that buried Cys157 is indeed accessible to
modiﬁcation (Figure 5B), indicating a ﬂexible and/or unstable
fold. We hypothesized that ATP binding may stabilize the
rTRPV1-ARD fold as it did hTRPV4-ARD. To test this
hypothesis biochemically, we took advantage of the modiﬁable
property of Cys157 to test the accessibility of this residue in the
presence or absence of ATP. The single-cysteine variant
rTRPV1-ARD CL-TRPV1-ARD C157 was chemically modiﬁed
by PEG-maleimide with a half-time of 4 min (t1/2 = 4 min) at
room temperature (Figure 5C,D). Incubation with 10 mM ATP
greatly inhibited the reaction, with a t1/2 of 52 min, consistent
with ATP stabilizing rTRPV1-ARD and limiting access to
buried Cys157. In contrast, incubation with 10 mM ADP, a
poor rTRPV1-ARD ligand,
7 only weakly inhibited Cys157
modiﬁcation (t1/2 = 10 min). CL-TRPV1-ARD C362,
containing a single surface-exposed cysteine in the disordered
C-terminal tail of the rTRPV1-ARD construct, was rapidly
modiﬁed (t1/2 < 30 s) even in the presence of nucleotides,
conﬁrming that ATP speciﬁcally inhibits the reaction of buried
Cys157 (Figure 5C,D). Therefore, as shown for hTRPV4-ARD
above using CD spectroscopy, cysteine modiﬁcation of
hTRPV4-ARD and rTRPV1-ARD indicates that ATP binding
can stabilize the TRPV-ARD fold.
To further conﬁrm our results, we used steered molecular
dynamics (SMD)
45 to pull the termini of TRPV1-ARD and
reveal stable regions during protein mechanical unfolding in
silico. The N- and C-termini were separated at a constant
velocity of 2 or 20 nm/ns in the presence or absence of bound
ATP. TRPV1-ARD simulated in the absence of bound ATP
unfolded at both ends, with repeats 6 and then 1 unraveling
during the time periods of independent simulations performed
at either stretching speed (Figure 5E,F). In contrast, when
ATP, bound to repeats 1−3, was included in the simulations,
repeat 6 and much of repeat 5 unravelled, while repeat 1
remained essentially intact (Figure 5G,H). Unfolding forces
were similar in the presence or absence of bound ATP at fast
stretching speeds, but slightly larger for the ATP-bound ARD in
the slower stretching simulations (Figure S2 of the Supporting
Information). These simulations therefore support the idea that
ATP stabilizes the surrounding local TRPV1-ARD structure.
Dynamic ligand-induced changes in TRPV-ARD stability may
therefore provide a regulatory mechanism for channel
sensitivity and activation.
Structural Analysis of TRPV4 Mutations Associated
with Human Diseases. Many mutations in the TRPV4 gene
have been associated with inherited diseases.
23,24 Within the
ARD, at least 15 mutations at 12 residues have been reported to
cause autosomal dominant diseases classiﬁed as either neuro-
pathies or skeletal dysplasias (Figure 6A).
46−48 Mutations at
arginine residues located on the convex face of hTRPV4-ARD
are associated with neuropathies (Figure 6B).
49 Arg232 and
Arg269 are located on Fingers 2 and 3, respectively, while
Arg315 and Arg316 are located at the base of Finger 4. In
contrast, eight residues whose mutations are associated with
skeletal dysplasias (Glu183, Lys197, Leu199, Glu278, Thr295,
Ile331, Asp333, and Val342) are spread on both ﬁngers and
helices, primarily on the concave face of hTRPV4-ARD (Figure
2B). Therefore, mapping the available genetic data on the
hTRPV4-ARD structure suggests that the phenotypic diﬀer-
ences of the diseases may be related to the diﬀering functional
properties of the concave and convex ARD surfaces.
To gain insights into possible biochemical mechanisms
connecting the mutations with disease phenotypes, we
generated mutant hTRPV4-ARD corresponding to 13 of the
15 disease-causing mutations located within the ARD. We were
not able to produce recombinant T295A hTRPV4-ARD
because of its low level of protein expression and/or stability.
The inability of T295A to fold stably when expressed in E. coli
and the inﬂuence of nucleotide ligands on the thermal stability
of hTRPV4-ARD suggest that several mutations could aﬀect
protein folding and/or stability. We therefore tested the
Figure 4. Eﬀect of ATP on hTRPV4-ARD thermal stability. (A)
Representative circular dichroism spectra of the puriﬁed TRPV4-ARD
protein (3.4 μM) in the presence of ATP, AMP, or phosphate (1 mM
each) at 10 °C. The wavelength (λ) of 222 nm used for
thermostability assays is indicated by a vertical red line. (B)
Representative traces of the thermostability assay. The molar ellipticity
at 222 nm was measured as the protein solutions were heated at a rate
of 1 °C/min. (C) Tm of TRPV4-ARD in the presence of 1 mM ATP,
AMP, or phosphate. The statistical signiﬁcance of the change in Tm
was determined by a multiple-comparison test using the Tukey−
Kramer method, with p < 0.05 and p < 0.01 indicated by one asterisk
and two asterisks, respectively.
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hTRPV4-ARD mutants by CD spectroscopy. Wild-type
hTRPV4-ARD had a melting temperature (Tm) of 37.93 ±
0.08 °C (note that a phosphate-based buﬀer was used for these
experiments). The Tm values of most mutants were signiﬁcantly
diﬀerent from that of the wild type, except for those of R232C
and I331T [38.1 ± 0.1 and 37.97 ± 0.07 °C, respectively
(Table S4 and Figure S3 of the Supporting Information)]. Most
mutations resulted in a signiﬁcantly lower Tm values, although
R269C showed a signiﬁcantly higher Tm (38.6 ± 0.2 °C) than
the wild type (Table S4 of the Supporting Information). L199F
and E183K showed the more severe reductions in Tm (32.9 ±
0.1 and 33.78 ± 0.06 °C, respectively). Leu199 is buried and
tightly packed between inner helices 2 and 3, and therefore, its
substitution with a larger phenylalanine side chain likely aﬀects
the protein thermal stability by disrupting the hydrophobic core
packing arrangement (Figure 6C). Glu183 is on the surface of
Finger 2 and forms a salt bridge to Arg232 in some of the
hTRPV4-ARD structures (Figure 6D). However, simple
disruption of this salt bridge is unlikely to cause this decrease
in stability because the complementary R232C neutralizing
mutation did not signiﬁcantly alter the Tm of hTRPV4-ARD.
The E183K charge reversal may cause electrostatic repulsion
between the ANK ﬁngers due to the proximity of Arg232, while
the R232C mutation, disrupting the salt bridge, would not
actively cause electrostatic repulsion. Overall, the averaged Tm
Figure 5. Eﬀect of ATP binding on protein stability in rTRPV1-ARD. (A) Structure of TRPV1-ARD (gray) bound to ATP (green, sticks), with
buried Cys157 highlighted (spheres). (B) TRPV1-ARD is modiﬁed at cysteine residues by PEG-maleimide (mPEG), causing an electrophoretic
mobility shift on a Coomassie-stained SDS gel. Abbreviations: WT, wild type; CL, a cysteine-less variant; C157, CL-TRPV1-ARD C157 single-
cysteine variant. Shown is a representative Coomassie-stained gel from one of three experiments. (C) Time course for modiﬁcation of single-cysteine
TRPV1-ARD variants C157 and C362 with 0.5 mM mPEG at room temperature. (D) Data from four experiments like that depicted in panel C were
quantiﬁed, and the mean ± standard deviation was plotted. (E and F) Molecular dynamics simulation in which the termini of the ATP-bound
TRPV1-ARD (E) or TRPV1-ARD structure with ATP removed prior to equilibrating the system (F) are pulled apart at a rate of 20 nm/ns.
Superimposed are the structures at the start (gold) and end (blue) of the simulations. (G and H) Root-mean-square deviation of each Cα atom over
the course of the simulation mapped onto the starting models with (G) or without (H) ATP. The change in color from blue to red indicates changes
in rmsd from 0 to 80 Å. Simulations in which the termini were pulled apart at a rate of 2 nm/ns gave similar results. See Table S3 of the Supporting
Information for experimental details.
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signiﬁcantly lower than those of the wild type (37.93 ± 0.08
°C; n =8 ;p = 0.0005) and neuropathy mutants (36.9 ± 1.5 °C;
n = 15; p = 0.017), although not all mutants obey this trend
(Figure 7A).
ATP Binding by hTRPV4-ARD Mutants. Most disease-
associated mutations in TRPV4-ARD cause substitutions of
surface-exposed side chains. This suggests that interactions with
other factors, such as other regions of the TRPV4 protein and/
or regulatory ligands, are aﬀected. Because ATP is a known
ligand, we tested the ability of the hTRPV4-ARDs with disease-
causing mutations to bind ATP using an ATP-agarose pull-
down assay (Figure 7B,C). Four mutants, K197R, R232C,
R269H, and V342F, showed signiﬁcantly weakened ATP
binding. Lys197, which directly interacts with ATP in our
ATP-bound hTRPV4-ARD structure (Figure 3B), showed one
of the greatest reductions in the level of ATP binding. This is
also consistent with previously published experiments in which
corresponding residues Lys183 of cTRPV4-ARD and Lys160 of
rTRPV1-ARD were shown to be crucial for ATP binding.
7,8 In
contrast, the reduction in the level of ATP binding observed for
R232C and R269H is surprising because both residues are on
the surface opposite the ATP-binding site (Figure 6B).
Similarly, ATP binding is signiﬁcantly enhanced by the
E183K and E278K mutations, although these residues also
have no direct interaction with ATP. These results suggest that,
although the interaction of ATP is speciﬁc to the ATP-binding
site observed in our structure,
8 it is inﬂuenced by the general
Figure 6. Mutations associated with human diseases in hTRPV4-ARD. (A) Positions of mutations associated with human inherited diseases that lie
within hTRPV4-ARD. Abbreviations: SEDM, spondyloepiphyseal dysplasia, type Maroteaux; SMDK, spondylometaphyseal dysplasia, type
Kozolowski; MD, metatropic dysplasia; SMA, spinal muscular atrophy; SPMA, scapuloperoneal spinal muscular atrophy; CMTC2, Charcot-Marie-
Tooth disease type 2C; HMSN2C, hereditary motor and sensory neuropathy 2C. This ﬁgure was inspired by ref 51. (B) Location of the disease-
causing mutations within TRPV4-ARD. Shown as spheres are 12 residue positions at which a total of 15 mutations causing human inherited diseases
have been identiﬁed. The ATP molecule is shown as sticks. Skeletal dysplasia and neurophathy mutations are depicted as green and blue spheres,
respectively. (C) Leu199 is located at the hydrophobic interface between ANK2 and ANK3. (D) Glu183 and Arg232 form a salt bridge on the
convex face of TRPV4-ARD.
Figure 7. Thermal stability and ATP binding of hTRPV4-ARD
mutants associated with inherited diseases. (A) The Tm determined by
CD spectrometry in a phosphate-based buﬀer is plotted for wild-type
and mutant hTRPV4-ARDs. The statistical signiﬁcance is shown in
Table S4 of the Supporting Information. (B) Coomassie-stained gels
show wild-type and mutant TRPV4-ARDs loaded (top) and bound to
ATP-agarose (bottom). (C) Normalized intensity of recovered protein
(mean ± SD; n = 3). The statistical signiﬁcance of the change in
binding to ATP-agarose with respect to wild type (WT) was
determined by a multiple-comparison test using Dunnett’s method,
with p < 0.05 and p < 0.01 indicated by one asterisk and two asterisks,
respectively.
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ATP sensitizes TRPV4 channel activity,
8 enhanced ATP
binding may result in higher channel activity, leading to
constitutive basal activity. However, although several mutations
either impaired or enhanced ATP binding, there was no
correlation between the disease phenotypes and the ATP-
binding phenotype.
In summary, enhanced ATP binding in E183K and E278K
could contribute to the constitutive TRPV4 activity that is
thought to lead to the TRPV4-linked disease phenotypes.
However, it is diﬃcult to explain the diﬀerent disease
phenotypes observed, including neuropathy and skeletal
dysplasia, on the basis of only changes in thermal stability or
ATP binding (Figure 7A,C), suggesting complex and
unidentiﬁed mechanisms for regulating TRPV4 channel activity
in diﬀerent tissues.
■ DISCUSSION
In this study, we determined the structures of ATP-free and
-bound hTRPV4-ARD and compared them with the structures
of other TRPV-ARDs. Structural analyses revealed the ﬂexible
Finger 3 as a possible switch for regulating channel activity.
Biochemical analyses and MD simulations indicated that ATP
contributed to protein stability in TRPV-ARDs possessing ATP
binding ability. Finally, a series of biochemical analyses of the
disease-associated mutants showed that several have impaired
thermal stability and/or ATP binding ability.
The new pair of crystal structures of the ATP-free and
-bound forms of TRPV4-ARD revealed minimal conforma-
tional changes in the presence of bound ligand. The long and
ﬂexible Finger 3 undergoes the largest conformational change.
In the process, a patch of aromatic residues is aﬀected, such that
a number of these aromatic residues are buried in the presence
of ATP. This suggests that a regulatory signal could be exposed
or hidden by a Finger 3 conformational change, to aﬀect the
sensitization of TRPV4 and the related TRPV1 channel by
ATP.
7,8 In other words, ATP binding may control the
accessibility of a regulatory surface, which could interact
intramolecularly with other parts of the TRPV4 channel or
intermolecularly with additional regulatory factors. One
candidate for such a regulatory factor is calmodulin, which
was shown to require residues within the ATP-binding site for
binding to TRPV4-ARD.
8
It is interesting that the ATP-bound ARD structures of both
TRPV1 and TRPV4, with their packed forms of Finger 3, are
similar to those of TRPV2 and TRPV6, which lack the ability to
bind ATP. Although it does not bind ATP, in phylogenetic
analyses TRPV2 clusters with TRPV1, TRPV3, and TRPV4,
which can bind ATP. This clustering and the fact that most
ATP-binding residues, including two critical lysines, are
conserved in TRPV2
8 suggest that TRPV2 may have lost its
ATP binding ability in a relatively recent evolutionary process.
A previous study attempted to generate a TRPV2-ARD mutant
that could bind ATP and/or CaM by introducing two
mutations: D78N, which neutralizes a negatively charged side
chain in the proximity of the phosphate interaction site, and
H165Q, which could restore the adenine-binding pocket.
8
Although neither of the single mutants bound ATP, the D78N/
H165Q double mutant bound ATP weakly but signiﬁcantly,
suggesting that additional residues are essential for ATP
binding. Our structure of ATP-bound TRPV4-ARD suggests
a candidate, Phe231, which is conserved in the rTRPV1-ARD
ATP-binding site (Tyr194) but not in TRPV2 and TRPV6
(Figure 3D). Comparing the TRPV-ARD structures suggests
that this aromatic residue buttresses the adenine-binding
pocket.
Several lines of evidence indicate that ATP binding increases
the protein stability of both TRPV1- and TRPV4-ARD (Figures
4 and 5 and Figure S1 of the Supporting Information).
Interestingly, TRPV4-ARD showed a Tm near body temper-
ature (37.1 ± 0.1 °C), suggesting that the ARD could be quite
sensitive to changes in physiological temperature. In such a
situation, a small but signiﬁcant increase in Tm induced by
binding of a ligand such as that observed here for ATP (37.9 ±
0.2 °C) may make a large contribution to protein stability at
body temperature. It has been reported that TRPV4 is activated
by warm temperatures (threshold for activation of ∼34 °C) and
shows basal constitutive activity around body temperature.
13
Furthermore, it has been suggested that some unfolding event
may be responsible for the thermosensitivity of TRP
channels.
50 Therefore, ARD stabilization by ligand binding
may ﬁne-tune TRPV4 function and basal activity levels,
although the relationship between the stability of ARD and
channel activity remains speculative.
TRPV4 is unusual among the TRPV ion channels because a
large number of dominant missense mutations that cause a
whole spectrum of human skeletal dysplasias and neuro-
degenerative diseases have been identiﬁed. In particular, the
neurodegenerative disease-causing mutations all localize to one
surface of the ARD.
49 In contrast, the skeletal dysplasia
mutations spread throughout the protein,
51 although a number
of them are found in the ARD. We studied a total of 15
mutations at 12 positions localized to the ARD, ﬁve
neurodegenerative disease mutations and 10 skeletal dysplasia
mutations. Recently, two new mutations, Q239H (associated
with skeletal dysplasia and located within the adenine pocket of
the ATP-binding site) and R316H (associated with CMT2C
like the previously identiﬁed R316C), have been reported in the
ARD.
52,53 Several hTRPV4 mutants, including both neuro-
degenerative mutations (R232C, R269C, R269H, R315W, and
R316C) and skeletal dysplasia mutations (I331F and D333G),
cause high basal activity and enhanced response to stimuli when
expressed heterologously in HEK293 cells and were inferred to
cause cell death because of high Ca2+ inﬂux.
26−28,46,53−55 The
constitutive activity of hTRPV4 mutants is consistent with their
dominant disease phenotypes. However, how diﬀerent tissue-
speciﬁc phenotypes are observed when both types of mutations
result in a similar cellular phenotype remains unexplained.
We therefore generated 13 of the ARD mutant proteins and
compared several of their biochemical properties. We did ﬁnd
several mutations causing signiﬁcant enhancement or reduction
in ARD thermal stability and/or ATP binding. These changes
could play a part in the disease mechanisms. Most hTRPV4-
ARD mutants showed signiﬁcantly reduced thermal stability,
suggesting that the ARD thermal stability may contribute to the
regulation of channel activity. For example, the ARD stability
could alter the functional channel population as the N-terminus
of TRPV4 has been reported to be important for tetramer
assembly.
56 However, a lower Tm does not provide a general
correlation to TRPV4 function because R269C, which showed
a Tm higher than that of the wild type, has been reported to
cause the constitutive activity of the channel.
27,28 Of note, the
enhanced ATP binding by two skeletal dysplasia mutations,
E183K and E278K, suggests a mechanism for increased TRPV4
activity and Ca2+ inﬂux because intracellular ATP has been
shown to sensitize TRPV4.
8
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mechanisms for how mutations in TRPV4-ARD aﬀect channel
activity: reduced ARD thermal stability and enhanced ATP
binding. However, it is diﬃcult to explain the disease-speciﬁc
segregation on the basis of only these two biochemical
phenotypes, suggesting that additional mechanisms are likely
at play in the regulation of the TRPV4 channel. We also did not
see a correlation between thermal stability and ATP binding,
suggesting that there is no clear functional relationship between
these two phenotypes. Our results therefore leave us with two
broad hypotheses. (1) Disease-causing TRPV4 mutations aﬀect
diverse regulatory mechanisms, converging to bone or neuron-
related phenotypes in how they ultimately aﬀect TRPV4
activity. (2) The most important common mechanisms remain
to be identiﬁed. That is, there could be regulatory factors or
mechanisms speciﬁc to each tissue. Further understanding of
the mechanisms that cause the human inherited diseases will
therefore require the identiﬁcation of tissue-speciﬁc biochem-
ical phenotypes, as well as additional cell biology and
electrophysiology studies to link biochemical ﬁndings to ion
channel function.
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